ABOUT 
SPECIALTY CARE
MCT2D leaders delivered presentations at the American Diabetes Association (ADA) annual conference in Orlando, Florida, last month.
Dr. Kara Mizokami-Stout and team presented a poster entitled "Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023." Included were some of the first published analyses of MCT2D registry data. The project found that among MCT2D participating practices, guideline-directed medication therapies (GDMT) for type 2 diabetes have increased since 2018. SGLT2i use is similar, and GLP-1 RA use is 2- 3 times higher than the rates reported in other studies.
Dr. Lauren Oshman led a session on statewide quality improvement and MCT2D's unique model as a Michigan Collaborative Quality Initiative.
Find the poster and the latest research publications from MCT2D on our Publications page.
Subscribe to the MCT2D Newsletter
Once per month we deliver news, updates, events, and more directly to you!
ccteam@mct2d.org
Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.